HIV Point-of-Care Test Evaluation in Infants

HIV Clinical Trial

— BABY  

Official title:

HIV Point-of-Care Tests in Babies Study (BABY) - Operational Evaluation of HIV Point-of-Care Tests for Very Early Infant HIV Diagnostics in Infants Born to HIV Infected Mothers in Mbeya, Tanzania

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02545296
• Other study ID #: LMU-IMPH-BABY-01
• Status: Completed
• Phase: N/A
• First received: July 8, 2015
• Last updated: March 6, 2018
• Start date: July 2015
• Est. completion date: August 2017

Study information

• Verified date: March 2018
• Source: Ludwig-Maximilians - University of Munich
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

HIV Point-of-Care tests in Babies Study (BABY) - Operational evaluation of HIV Point-of-Care tests for very early infant HIV diagnostics in infants born to HIV infected mothers in Mbeya, Tanzania.

Description:

This in-vitro diagnostic (IVD) study in infants born to HIV infected mothers evaluates the reliability and operational feasibility of an HIV Point-of-Care (PoC) test for HIV early infant diagnosis (EID) in a public health setting at obstetric clinics in Mbeya, Tanzania.

Recruitment is planned to take place at 4 obstetric/maternity study sites in and around Mbeya over a time period of 12 months. The HIV PoC test will be validated against the Standard-of-Care diagnostic test, i.e. Dried Blood Spot (DBS) analyses.

The PoC test under investigation is the Xpert HIV-1 Qual produced by Cepheid, Sunnyvale, USA.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 604
• Est. completion date: August 2017
• Est. primary completion date: October 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 48 Hours

Eligibility

Inclusion Criteria:

1. Voluntary and informed consent of the mother for her own study participation (if applicable).

2. Voluntary and informed consent of the legal guardian of the child for participation of the child in the study.

3. Mothers/legal guardians =18 years of age.

4. Documented maternal HIV infection.

5. Willingness to consent to HIV testing for the child and herself (if applicable).

6. Willing to consent to active tracing including home tracing.

Exclusion Criteria:

1. Deficiency in the mother, rendering it difficult, if not impossible, for her or her infant to take part in the study or understand the information provided to her. This includes alcoholism, drug dependency as well as psychiatric illnesses, suicidal tendencies or any other inability.

2. Having delivered more than 48h ago

3. Prisoners

4. Women presenting with an emergency requiring immediate medical assistance if not resolved at study inclusion.

5. Stillbirths

6. Infant requiring emergency care or born with severe malformation.

7. If within the discretion of the investigator based on recommendation of the gynaecologist or paediatrician in charge study participation would possibly add not acceptable risk or burden to the mother or infant (e.g. significant congenital malformation, health deficiencies, very low birth weight less than 1500g)

8. Unlikely to comply with protocol as judged by the principal investigator or his designate

Related Conditions & MeSH terms

• HIV

Intervention

Other:
• In-vitro Diagnostics
Ex-vivo performed diagnostic blood based test.

Locations

Country	Name	City	State
Tanzania	NIMR - Mbeya Medical Research Centre	Mbeya

Sponsors (2)

Lead Sponsor	Collaborator
Michael Hoelscher	German Center for Infection Research

Country where clinical trial is conducted

Tanzania, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Specificity of PoC HIV test	Specificity of the PoC HIV test	Participants are planned to be followed for the duration of 6 weeks, i.e. the time point of the current Standard of Care EID
Primary	Sensitivity of PoC HIV test	Sensitivity of the PoC HIV test	Participants are planned to be followed for the duration of 6 weeks, i.e. the time point of the current Standard of Care EID